You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
|
|---|---|
| Published in |
Journal of Clinical Oncology, November 2018
|
| DOI | 10.1200/jco.18.00131 |
| Pubmed ID | |
| Authors |
Nathan A. Pennell, Joel W. Neal, Jamie E. Chaft, Christopher G. Azzoli, Pasi A. Jänne, Ramaswamy Govindan, Tracey L. Evans, Daniel B. Costa, Heather A. Wakelee, Rebecca S. Heist, Marc A. Shapiro, Alona Muzikansky, Sudish Murthy, Michael Lanuti, Valerie W. Rusch, Mark G. Kris, Lecia V. Sequist |
X Demographics
The data shown below were collected from the profiles of 111 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 49 | 44% |
| France | 4 | 4% |
| United Kingdom | 4 | 4% |
| Mexico | 4 | 4% |
| Brazil | 3 | 3% |
| Australia | 2 | 2% |
| Switzerland | 2 | 2% |
| Italy | 2 | 2% |
| Canada | 2 | 2% |
| Other | 8 | 7% |
| Unknown | 31 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 61 | 55% |
| Scientists | 31 | 28% |
| Practitioners (doctors, other healthcare professionals) | 15 | 14% |
| Science communicators (journalists, bloggers, editors) | 4 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 125 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 16 | 13% |
| Student > Ph. D. Student | 13 | 10% |
| Researcher | 13 | 10% |
| Student > Bachelor | 11 | 9% |
| Lecturer | 9 | 7% |
| Other | 26 | 21% |
| Unknown | 37 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 42% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Nursing and Health Professions | 5 | 4% |
| Business, Management and Accounting | 2 | 2% |
| Other | 5 | 4% |
| Unknown | 45 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 106. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2022.
All research outputs
#407,528
of 25,782,229 outputs
Outputs from Journal of Clinical Oncology
#790
of 22,250 outputs
Outputs of similar age
#7,946
of 338,243 outputs
Outputs of similar age from Journal of Clinical Oncology
#8
of 159 outputs
Altmetric has tracked 25,782,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,250 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,243 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.